Daniel Latham, PhD Novartis

Dr. Daniel Latham is the Head of Device Development & LCM,  where he leads an organisation of around 120 associates responsible for the development and life cycle management of delivery systems of drug/device combinations for new biologic entities, biosimilars, and cell & gene therapy.

Over the past 13 years at Novartis, he has overseen many device and primary packaging developments, approvals and launches and has significantly supported the growth and understanding of device development and drug/device interaction within the organisation.

Prior to Novartis, he held a variety of roles in consumer health­care, focusing on the development and marketing of OTC medicines, transdermal patches, and medical devices.

He has a Ph.D. in controlled drug delivery from Queen Mary, Uni­versity of London and a Bachelor’s degree and Master’s degrees in Engineering and Medical Physics from the University of Sheffield’